Please login to the form below

Repligen

This page shows the latest Repligen news and features for those working in and with pharma, biotech and healthcare.

Other companies working on therapies for SMA includeand Pfizer/Repligen.

Pfizer acquires spinal muscular atrophy research programme

Gains rights to drug candidate RG3039 in deal with Repligen that could be worth up to $70m. ... $5m. The main candidate involved in the programme is RG3039, which will undergo phase I trials carried out by Repligen in the first quarter of 2013.
Oncology bias in pharma deals

112. Syntaxin/Ipsen. Research and development collaboration. Botulinum toxins. 99. Novozymes Biopharma Sweden/Repligen Corp.
Repligen bipolar drug fails in study

An oral form of uridine being developed by Repligen as a potential treatment for bipolar depression failed to show efficacy in a late-stage clinical trial. ... However, Repligen noted that a preliminary analysis indicates that in the 50 patients in the
State of mind

RG 2417. Repligen. Bipolar disorder. Anticonvulsants. Anticonvulsants, such as lamotrigine and valproic acid, have been found useful as mood stabilisers, preventing the extremes of mania and depression in patients with bipolar ... RG 2417 (Repligen) is a

More from news
Approximately 2 fully matching, plus 3 partially matching documents found.

Pharma deals during January 2013

Repligen announced the signature of an exclusive worldwide licensing agreement with Pfizer to advance Repligen's spinal muscular atrophy (SMA) programme. ... Acquisition. Antibody manufacturer. 70. Repligen / Pfizer. Licence. RG3039 orphan for spinal